These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 3693868)

  • 21. Blood levels of haloperidol in schizophrenic patients.
    Shvartsburd A; Dekirmenjian H; Smith RC
    J Clin Psychopharmacol; 1983 Feb; 3(1):7-12. PubMed ID: 6833528
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pretreatment plasma HVA predicts neuroleptic response in manic psychosis.
    Mazure CM; Bowers MB
    J Affect Disord; 1998 Feb; 48(1):83-6. PubMed ID: 9495606
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
    Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M
    Encephale; 1995; 21(6):417-24. PubMed ID: 8674466
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risperidone in the treatment of psychotic depression.
    Goto M; Yoshimura R; Kakihara S; Shinkai K; Yamada Y; Kaji K; Ueda N; Nakamura J
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jun; 30(4):701-7. PubMed ID: 16580110
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The relationship between prolactin response and clinical efficacy of risperidone in acute psychotic inpatients.
    Lee BH; Kim YK
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jun; 30(4):658-62. PubMed ID: 16466670
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasma prolactin and plasma homovanillic acid: predictors of clinical response in schizophrenia.
    Davila R; Gonzalez MA; Zumarraga M; Andia I; Guimon J; Silva RR; Friedhoff AJ
    Biol Psychiatry; 1995 Aug; 38(4):267-9. PubMed ID: 8547450
    [No Abstract]   [Full Text] [Related]  

  • 27. Lithium in combination with perphenazine: effect on plasma monoamine metabolites.
    Bowers MB; Mazure CM; Nelson JC; Jatlow PI
    Biol Psychiatry; 1992 Dec; 32(12):1102-7. PubMed ID: 1477190
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasma/RBC haloperidol ratios and improvement in acute psychotic symptoms.
    Neborsky RJ; Janowsky DS; Perel JM; Munson E; Depry D
    J Clin Psychiatry; 1984 Jan; 45(1):10-3. PubMed ID: 6363395
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acutely psychotic patients receiving high-dose haloperidol therapy.
    Remington G; Pollock B; Voineskos G; Reed K; Coulter K
    J Clin Psychopharmacol; 1993 Feb; 13(1):41-5. PubMed ID: 8486816
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Etiologic heterogeneity of the psychoses: is there a dopamine psychosis?
    Garver DL; Steinberg JL; McDermott BE; Yao JK; Ramberg JE; Lewis S; Kingsbury SJ
    Neuropsychopharmacology; 1997 Mar; 16(3):191-201. PubMed ID: 9138435
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pretreatment plasma HVA and haloperidol response in acute mania.
    Chou JC; Czobor P; Tuma I; Charles O; Bebe R; Cooper TB; Chang WH; Lane HY; Stone DL
    J Affect Disord; 2000 Jul; 59(1):55-9. PubMed ID: 10814771
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early neuroleptic response: clinical profiles and plasma catecholamine metabolites.
    Bowers MB; Swigar ME; Jatlow PI; Hoffman FJ; Goicoechea N
    J Clin Psychopharmacol; 1987 Apr; 7(2):83-6. PubMed ID: 2884237
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characteristics of patients with the highest plasma catecholamine metabolite levels.
    Bowers MB; Swigar ME; Hoffman FJ; Goicoechea N
    Am J Psychiatry; 1988 Feb; 145(2):246-8. PubMed ID: 3422545
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
    Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
    J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Studies of catecholamine metabolism in schizophrenia/psychosis--II.
    Maas JW; Contreras SA; Miller AL; Berman N; Bowden CL; Javors MA; Seleshi E; Weintraub SE
    Neuropsychopharmacology; 1993 Feb; 8(2):111-6. PubMed ID: 8471122
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasma homovanillic acid levels and therapeutic outcome in schizophrenics: comparisons of neuroleptic-naive first-episode patients and patients with disease exacerbation due to neuroleptic discontinuance.
    Akiyama K; Tsuchida K; Kanzaki A; Ujike H; Hamamura T; Kondo K; Mutoh S; Miyanagi K; Kuroda S; Otsuki S
    Biol Psychiatry; 1995 Nov; 38(10):639-48. PubMed ID: 8555375
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of neuroleptics on platelet monoamine oxidase activity.
    Ho BT; Smith RC; Kralik P; Allen R; Schoolar J; Khan M; DeJohn C
    Biol Psychiatry; 1982 Aug; 17(8):885-95. PubMed ID: 6126230
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Pharmacokinetic of haloperidol decanoate in psychotic patients (author's transl)].
    Parent M; Toussaint C; Driesens F; Gelders Y
    Acta Psychiatr Belg; 1981; 81(4):399-406. PubMed ID: 7331843
    [No Abstract]   [Full Text] [Related]  

  • 39. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasma haloperidol levels and clinical response: confounding variables.
    Mavroidis ML; Garver DL; Kanter DR; Hirschowitz J
    Psychopharmacol Bull; 1985; 21(1):62-5. PubMed ID: 3983340
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.